These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 25367684)

  • 21. Interleukin-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas.
    Sawada R; Ku Y; Akita M; Otani K; Fujikura K; Itoh T; Ajiki T; Fukumoto T; Kakeji Y; Zen Y
    Histopathology; 2018 Aug; 73(2):259-272. PubMed ID: 29675965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.
    Liau JY; Tsai JH; Yuan RH; Chang CN; Lee HJ; Jeng YM
    Mod Pathol; 2014 Aug; 27(8):1163-73. PubMed ID: 24406866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative clinicopathological study of biliary intraductal papillary neoplasms and papillary cholangiocarcinomas.
    Fujikura K; Fukumoto T; Ajiki T; Otani K; Kanzawa M; Akita M; Kido M; Ku Y; Itoh T; Zen Y
    Histopathology; 2016 Dec; 69(6):950-961. PubMed ID: 27410028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma.
    Gu M
    Int J Clin Exp Pathol; 2015; 8(1):862-6. PubMed ID: 25755787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
    Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J
    World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrahepatic clear cell cholangiocarcinoma: immunohistochemical aspects in a very rare type of cholangiocarcinoma.
    Haas S; Gütgemann I; Wolff M; Fischer HP
    Am J Surg Pathol; 2007 Jun; 31(6):902-6. PubMed ID: 17527078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sox9 expression in carcinogenesis and its clinical significance in intrahepatic cholangiocarcinoma.
    Matsushima H; Kuroki T; Kitasato A; Adachi T; Tanaka T; Hirabaru M; Hirayama T; Kuroshima N; Hidaka M; Soyama A; Takatsuki M; Kinoshita N; Sano K; Nishida N; Eguchi S
    Dig Liver Dis; 2015 Dec; 47(12):1067-75. PubMed ID: 26341967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered mucin gene expression in stone-containing intrahepatic bile ducts and cholangiocarcinomas.
    Lee KT; Liu TS
    Dig Dis Sci; 2001 Oct; 46(10):2166-72. PubMed ID: 11680592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelial-mesenchymal transition phenotypes are associated with patient survival in intrahepatic cholangiocarcinoma.
    Gu MJ; Choi JH
    J Clin Pathol; 2014 Mar; 67(3):229-34. PubMed ID: 24062361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of the anterior gradient protein-2 is a conserved feature during morphogenesis and carcinogenesis of the biliary tree.
    Lepreux S; Bioulac-Sage P; Chevet E
    Liver Int; 2011 Mar; 31(3):322-8. PubMed ID: 21281432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bile duct expression of pancreatic and duodenal homeobox 1 in perihilar cholangiocarcinogenesis.
    Igarashi S; Matsubara T; Harada K; Ikeda H; Sato Y; Sasaki M; Matsui O; Nakanuma Y
    Histopathology; 2012 Aug; 61(2):266-76. PubMed ID: 22594685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma.
    Ryu HS; Chung JH; Lee K; Shin E; Jing J; Choe G; Kim H; Xu X; Lee HE; Kim DG; Lee H; Jang JJ
    Hum Pathol; 2012 Dec; 43(12):2360-70. PubMed ID: 23084587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma.
    Huang YC; Chen M; Shyr YM; Su CH; Chen CK; Li AF; Ho DM; Chen YM
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1384-9. PubMed ID: 18624901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.
    Goeppert B; Frauenschuh L; Renner M; Roessler S; Stenzinger A; Klauschen F; Warth A; Vogel MN; Mehrabi A; Hafezi M; Boehmer K; von Deimling A; Schirmacher P; Weichert W; Capper D
    Mod Pathol; 2014 Jul; 27(7):1028-34. PubMed ID: 24309328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma.
    Xu Y; Zhu M; Zhang S; Liu H; Li T; Qin C
    Pathol Oncol Res; 2010 Jun; 16(2):169-75. PubMed ID: 19757198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulators of apoptosis in cholangiocarcinoma.
    Jhala NC; Vickers SM; Argani P; McDonald JM
    Arch Pathol Lab Med; 2005 Apr; 129(4):481-6. PubMed ID: 15794670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts.
    Minato H; Nakanuma Y; Terada T
    Histopathology; 1996 May; 28(5):411-9. PubMed ID: 8735716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma.
    Terashita K; Chuma M; Hatanaka Y; Hatanaka K; Mitsuhashi T; Yokoo H; Ohmura T; Ishizu H; Muraoka S; Nagasaka A; Tsuji T; Yamamoto Y; Kurauchi N; Shimoyama N; Toyoda H; Kumada T; Kaneoka Y; Maeda A; Ogawa K; Natsuizaka M; Kamachi H; Kakisaka T; Kamiyama T; Taketomi A; Matsuno Y; Sakamoto N
    J Clin Pathol; 2016 Jul; 69(7):593-9. PubMed ID: 26670746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver fluke-associated and sporadic cholangiocarcinoma: an immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes.
    Hughes NR; Pairojkul C; Royce SG; Clouston A; Bhathal PS
    J Clin Pathol; 2006 Oct; 59(10):1073-8. PubMed ID: 16679351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
    Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
    Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.